(Lebrikizumab)Biosimilar Reference Antibody-GS40367

货号：GS40367

Lebrikizumab is a humanized monoclonal antibody that selectively and with high affinity binds to and neutralizes interleukin-13 (IL-13), a key driver of type 2 inflammation. It specifically targets the IL-13 cytokine, preventing it from interacting with its receptor complex (IL-4Rα/IL-13Rα1). This blockade inhibits downstream inflammatory signaling involved in skin barrier dysfunction and itch. Lebrikizumab is approved in multiple regions (including the EU, UK, and Canada) for the treatment of moderate-to-severe atopic dermatitis (eczema) in adults and adolescents, with ongoing review by other agencies like the US FDA.